Related Experiment Video
Updated: Aug 11, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Rapid growth of Merkel cell carcinoma after treatment with rituximab
Marla L Wirges1, Frank Saporito, Jennifer Smith
1Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Abstract:
Merkel cell carcinoma is an uncommon neuroendocrine carcinoma of the skin. We report a case of rapid growth of Merkel cell carcinoma after treatment with rituximab, a new anti-CD20 monoclonal antibody, for acquired factor VIII inhibitor. We propose that rituximab may place patients at higher risk for aggressive Merkel cell carcinoma thus necessitating the need for increased long-term surveillance of these patients.
Related Concept Videos
Mitogens and the Cell Cycle
Abnormal Proliferation